Kodiak Sciences: DAYBREAK Needs To Deliver More Than A Passing Grade (NASDAQ:KOD)
· seekingalpha.com
Kodiak expects Phase 3 DAYBREAK results for Zenkuda and KSI-501 this month in wet AMD. Read why KOD stock is a hold.
Kodiak Sciences ( KOD ) has a credible chance to bring a longer-lasting treatment to the retinal drug market. The harder question is whether its coming clinical...